Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents

Cornelius VR, Liu K, Peacock J, Sauzet O (2016)
BMJ OPEN 6(3): e010599.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Cornelius, Victoria R.; Liu, Kun; Peacock, Janet; Sauzet, OdileUniBi
Abstract / Bemerkung
Objective To compare consistency of adverse drug reaction (ADR) data in publicly available product information documents for brand drugs, between the USA and Europe. To assess the usefulness of information for prescribers and patients. Design A comparison review of product information documents for antidepressants and anticonvulsants concurrently marketed by the same pharmaceutical company in the USA and Europe. Setting For each drug, data were extracted from the US Product Inserts and the European Summary of Product Characteristics documents between 09/2013 and 01/2015. Participants Individuals contributing ADR information to product information documents. Main outcomes measures All ADRs reported in product information sections 5 and 6 (USA), and 44 and 48 (Europe). Results Twelve brand drugs24 paired documentswere included. On average, there were 77 more ADRs reported in the USA compared with in the European product information document, with a median number of 201 ADRs (range: 65-425) and 114 (range: 56-265), respectively. More product information documents in the USA reported information on the source of evidence (10 vs 5) and risk (9 vs 5) for greater than 80% of ADRs included in the document. There was negligible information included regarding duration, severity, reversibility or recurrence of ADRs. On average, only 29% of ADR terms were reported in both paired documents. Conclusions Product information documents contained a large number of ADRs, but lacked contextual data and information important to patients and prescribers, such as duration, severity and reversibility. The ADR profile was found to be inconsistently reported between the USA and Europe, for the same drug. Identifying, selecting, summarising and presenting multidimensional harm data should be underpinned by practical evidence-based guidelines. In order for prescribers to provide considered risk-benefit advice across competing drug therapies to patients, they need access to comprehensible and reliable ADR information.
Stichworte
adverse drug reactions; antidepressent; anticonvulsants; Summary of; Product Characteristics; United States Product Inserts; product; infomation
Erscheinungsjahr
2016
Zeitschriftentitel
BMJ OPEN
Band
6
Ausgabe
3
Art.-Nr.
e010599
ISSN
2044-6055
Page URI
https://pub.uni-bielefeld.de/record/2903458

Zitieren

Cornelius VR, Liu K, Peacock J, Sauzet O. Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents. BMJ OPEN. 2016;6(3): e010599.
Cornelius, V. R., Liu, K., Peacock, J., & Sauzet, O. (2016). Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents. BMJ OPEN, 6(3), e010599. doi:10.1136/bmjopen-2015-010599
Cornelius, Victoria R., Liu, Kun, Peacock, Janet, and Sauzet, Odile. 2016. “Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents”. BMJ OPEN 6 (3): e010599.
Cornelius, V. R., Liu, K., Peacock, J., and Sauzet, O. (2016). Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents. BMJ OPEN 6:e010599.
Cornelius, V.R., et al., 2016. Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents. BMJ OPEN, 6(3): e010599.
V.R. Cornelius, et al., “Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents”, BMJ OPEN, vol. 6, 2016, : e010599.
Cornelius, V.R., Liu, K., Peacock, J., Sauzet, O.: Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents. BMJ OPEN. 6, : e010599 (2016).
Cornelius, Victoria R., Liu, Kun, Peacock, Janet, and Sauzet, Odile. “Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents”. BMJ OPEN 6.3 (2016): e010599.

2 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Analysis and reporting of adverse events in randomised controlled trials: a review.
Phillips R, Hazell L, Sauzet O, Cornelius V., BMJ Open 9(2), 2019
PMID: 30826796
Types, frequencies, and burden of nonspecific adverse events of drugs: analysis of randomized placebo-controlled clinical trials.
Mahr A, Golmard C, Pham E, Iordache L, Deville L, Faure P., Pharmacoepidemiol Drug Saf 26(7), 2017
PMID: 28176407

33 References

Daten bereitgestellt von Europe PubMed Central.

Adverse event reporting in randomised controlled trials of neuropathic pain: considerations for future practice.
Cornelius VR, Sauzet O, Williams JE, Ayis S, Farquhar-Smith P, Ross JR, Branford RA, Peacock JL., Pain 154(2), 2012
PMID: 23127360
The characteristics and quality of randomized controlled trials in neuropathic pain: a descriptive study based on a systematic review.
Sauzet O, Williams JE, Ross J, Branford R, Farquhar-Smith P, Griffith GL, Fox-Rushby JA, Peacock JL., Clin J Pain 29(7), 2013
PMID: 23042476

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Discrepancies in listed adverse drug reactions in pharmaceutical product information supplied by the regulatory authorities in Denmark and the USA.
Eriksson R, Aagaard L, Jensen LJ, Borisova L, Horluck D, Brunak S, Hansen EH., Pharmacol Res Perspect 2(3), 2014
PMID: 25505588
Contraindication labelling changes in the United States and Germany.
Garbe E, Andersohn F., Eur. J. Clin. Pharmacol. 63(1), 2006
PMID: 17124576

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Adverse events: the more you search, the more you find.
Ioannidis JP, Mulrow CD, Goodman SN., Ann. Intern. Med. 144(4), 2006
PMID: 16490917

Strom BaV, G null., 2013
A comparison of two medical terminologies in coding and analysing clinical trial safety data
Brown DR, Brown EG, Moulvad TB., 1997
Challenges in coding adverse events in clinical trials: a systematic review.
Schroll JB, Maund E, Gotzsche PC., PLoS ONE 7(7), 2012
PMID: 22911755
A quantitative analysis of adverse events and "overwarning" in drug labeling.
Duke J, Friedlin J, Ryan P., Arch. Intern. Med. 171(10), 2011
PMID: 21606101
Better reporting of harms in randomized trials: an extension of the CONSORT statement.
Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D; CONSORT Group., Ann. Intern. Med. 141(10), 2004
PMID: 15545678
Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest.
Boyce RD, Ryan PB, Noren GN, Schuemie MJ, Reich C, Duke J, Tatonetti NP, Trifiro G, Harpaz R, Overhage JM, Hartzema AG, Khayter M, Voss EA, Lambert CG, Huser V, Dumontier M., Drug Saf 37(8), 2014
PMID: 24985530
How much information about adverse effects of medication do patients want from physicians?
Ziegler DK, Mosier MC, Buenaver M, Okuyemi K., Arch. Intern. Med. 161(5), 2001
PMID: 11231703
What patients want to know about their medications. Focus group study of patient and clinician perspectives.
Nair K, Dolovich L, Cassels A, McCormack J, Levine M, Gray J, Mann K, Burns S., Can Fam Physician 48(), 2002
PMID: 11852597
Does patient education cause side effects? A controlled trial.
Howland JS, Baker MG, Poe T., J Fam Pract 31(1), 1990
PMID: 2193996
Can physicians warn patients of potential side effects without fear of causing those side effects?
Lamb GC, Green SS, Heron J., Arch. Intern. Med. 154(23), 1994
PMID: 7993161
Numbers matter to informed patient choices: a randomized design across age and numeracy levels.
Peters E, Hart PS, Tusler M, Fraenkel L., Med Decis Making 34(4), 2013
PMID: 24246563
Presenting Numeric Information with Percentages and Descriptive Risk Labels: A Randomized Trial.
Sinayev A, Peters E, Tusler M, Fraenkel L., Med Decis Making 35(8), 2015
PMID: 25952743
A systematic review of quantitative and qualitative research on the role and effectiveness of written information available to patients about individual medicines.
Raynor DK, Blenkinsopp A, Knapp P, Grime J, Nicolson DJ, Pollock K, Dorer G, Gilbody S, Dickinson D, Maule AJ, Spoor P., Health Technol Assess 11(5), 2007
PMID: 17280623
Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 26996819
PubMed | Europe PMC

Suchen in

Google Scholar